关注
Heidi Ko
Heidi Ko
Labcorp
在 covance.com 的电子邮件经过验证
标题
引用次数
引用次数
年份
Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma
NJ Short, HM Kantarjian, H Ko, JD Khoury, F Ravandi, DA Thomas, ...
American journal of hematology 92 (6), E114, 2017
502017
Poor outcomes associated with+ der (22) t (9; 22) and− 9/9p in patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia receiving chemotherapy plus a …
NJ Short, HM Kantarjian, K Sasaki, F Ravandi, H Ko, C Cameron Yin, ...
American journal of hematology 92 (3), 238-243, 2017
502017
Clinical utility of 18F-FDG PET/CT in staging localized breast cancer before initiating preoperative systemic therapy
H Ko, Y Baghdadi, C Love, JA Sparano
Journal of the National Comprehensive Cancer Network 18 (9), 1240-1246, 2020
402020
Hemolytic uremic syndrome associated with Escherichia coli O157:H7 infection in older adults: a case report and review of the literature
H Ko, H Maymani, C Rojas-Hernandez
Journal of Medical Case Reports 10, 1-4, 2016
392016
Predictors of survival in patients with advanced gastrointestinal malignancies admitted to the intensive care unit
H Ko, M Yan, R Gupta, K Kebbel, A Maiti, J Song, J Nates, MJ Overman
The oncologist 24 (4), 483-490, 2019
132019
Older age and increased neutrophil-to-lymphocyte ratio (NLR) are predictors of mortality in a multiethnic urban cohort of hematologic neoplasms and COVID-19 patients
A D'Aiello, S Zareef, K Pradhan, A Lombardo, F Khatun, J Mustafa, ...
Blood 136, 34-35, 2020
62020
The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer
MK Nesline, V Subbiah, RA Previs, KC Strickland, H Ko, P DePietro, ...
Oncology and Therapy, 1-15, 2024
52024
Cancer testis antigen burden (CTAB): a novel biomarker of tumor-associated antigens in lung cancer
RJ Seager, MF Senosain, E Van Roey, S Gao, P DePietro, MK Nesline, ...
Journal of Translational Medicine 22 (1), 141, 2024
32024
Transcriptomic analysis of GITR and GITR ligand reveals cancer immune heterogeneity with implications for GITR targeting
P Moussa, R Kurzrock, D Nishizaki, H Miyashita, S Lee, M Nikanjam, ...
American Journal of Cancer Research 14 (4), 1634, 2024
32024
The impact of single gene testing (SGT) on subsequent comprehensive genomic profiling (CGP) success in community oncology practice for advanced non-small cell lung cancer …
MK Nesline, P DePietro, M Cooper, S Zhang, S Howarth, ZD Wallen, ...
Journal of Clinical Oncology 41 (16_suppl), 6506-6506, 2023
32023
Immunologic Factors Associated with Differential Response to Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer
RJ Seager, H Ko, S Pabla, MF Senosain, P Kalinski, E Van Roey, S Gao, ...
Journal of Personalized Medicine 14 (5), 481, 2024
22024
Abstract PS4-30: Neutrophil-to-lymphocyte ratio or platelet-to-lymphocyte ratio as prognostic biomarkers in patients with metastatic breast cancer treated with CDK4/6 inhibitors
A Weiner, LS Munoz-Arcos, H Ko, J Anampa
Cancer Research 81 (4_Supplement), PS4-30-PS4-30, 2021
22021
Clinical utility of 18F-FDG-PET/CT in staging localized breast cancer prior to initiating preoperative systemic therapy.
H Ko, Y Baghdadi, C Love, JA Sparano
Journal of Clinical Oncology 38 (15_suppl), 563-563, 2020
22020
Clinical outcomes of acquired factor VIII inhibitors in cancer population: a systematic review
HC Ko, C Rojas Hernandez, TH Oo
Blood 130 (Supplement 1), 5639-5639, 2017
22017
Comprehensive assessment of immune phenotype and its effects on survival outcomes in HER2-low versus HER2-zero breast cancer
HC Ko, RJ Seager, S Pabla, MF Senosain, E Van Roey, S Gao, ...
Breast Cancer: Targets and Therapy, 483-495, 2024
12024
The predictive role of TNF-related genes in patients receiving immune checkpoint inhibitors
OE Ababneh, S Kato, D Nishizaki, H Miyashita, S Lee, M Nesline, S Pabla, ...
Cancer Research 84 (6_Supplement), 6393-6393, 2024
12024
87 Distinctions in Tumor Microenvironment Between PD-L1 Positive versus Negative Head and Neck Squamous Cell Carcinoma (HNSCC)
KS Saini, HC Ko, ZD Wallen, MF Green, KC Strickland, RA Previs, ...
Radiotherapy and Oncology 192, S20-S22, 2024
12024
Is HER2-Low a New Clinical Entity or Merely a Biomarker for an Antibody Drug Conjugate?
H Ko, RA Previs, KC Strickland, J Klein, B Caveney, C Chiruzzi, ...
Oncology and Therapy 12 (1), 13-17, 2024
12024
LAG3 landscape in solid tumors and its association with immunotherapy outcomes in non-small cell lung cancer.
R Seager, MF Senosain, E Van Roey, S Gao, P DePietro, MK Nesline, ...
Journal of Clinical Oncology 41 (16_suppl), e21113-e21113, 2023
12023
Analysis of real world FRα testing in ovarian, fallopian tube, and primary peritoneal cancers
RA Previs, KC Strickland, Z Wallen, H Ko, M Green, M Cooper, E Lyon, ...
Gynecologic Oncology 192, 102-110, 2025
2025
系统目前无法执行此操作,请稍后再试。
文章 1–20